ClinicalTrials.gg
CompletedNCT02694718Updated Jan 11, 2017Results posted

A Study of Capecitabine Plus Oxaliplatin in Combination With Pre-operative Pelvic Radiotherapy in Rectal Cancer

A Phase 2 interventional study of Capecitabine and Oxaliplatin in Rectal Cancer, sponsored by Hoffmann-La Roche. Completed at 6 sites in Switzerland. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2017-01-11.

Sponsored by Hoffmann-La Roche · Phase 2, Interventional, and Treatment

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Phase 2
Study type
Interventional
Enrollment
60
Allocation
Not applicable
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-17

Among 136 studies testing capecitabine in Rectal Neoplasms — 18 open to participants now, 28 under way, 4 of them phase 3. Capecitabine · Rectal Neoplasms.

Enrollment
48th of 130
60 · median 49
Started
2005
with 7 others
Phase 2
85 of 136
13 open now
Registered
92nd of 136
by date

Among the 136 studies testing capecitabine in Rectal Neoplasms, this one is the 48th largest by enrollment of the 130 interventional ones that give a count, is one of 8 that started in 2005, is one of 85 in phase 2, and was the 92nd registered.

Rectal Neoplasms

2,403 studies on the registry are indexed under Rectal Neoplasms; 589 are open to participants now.

Browse Rectal Neoplasms studies →

Open to participants now

18 of the 136 studies testing capecitabine in Rectal Neoplasms are open now, in 6 countries. Recruiting first, the newest first:

13 more — sign in →

By country, each count listing its studies:

All 18 open studies →

About capecitabine

Capecitabine: first FDA approval 1998 (XELODA), first EMA approval 2001. What it is approved for, and how studies give it, is on its page →

Who these studies take

Of the 406 Rectal Neoplasms studies recruiting now, 211 (52%) set no upper age limit and 143 (35%) stop at 75 or younger; 19 take children under 18; 16 take healthy volunteers.

This study: 18 Years and older · all sexes · no healthy volunteers.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 136 studies testing capecitabine in Rectal Neoplasms, or all of them as a file.
02

Study summary

The purpose of this study is to determine the pathological complete tumor response rate.

03

Conditions studied

  • Rectal Cancer

Browse trials for

04

Who can participate

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
No

Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.

Inclusion criteria

  • confirmed locally advanced T3/T4 rectal carcinoma with or without nodal involvement requiring surgery of the primary tumor
  • performance status 0-2
  • Adequate values of laboratory parameters

Exclusion criteria

Exclusion Criteria:

  • Evidence of distant
  • Previous Chemotherapy or immunotherapy for colorectal cancer
  • Previous radiotherapy to the pelvis
  • Pre-existing condition which would deter radiotherapy
  • within last 5 years, except cured basal cell cancer of the skin and in situ cancer of the cervix
  • cardiac disease or myocardial infarction within the last 12 months
  • Lack of physical integrity of the upper gastrointestinal tract or those who have malabsorption syndrome
  • Organ allografts
  • Concomitant treatment with brivudine, lamivudine, ribavirin or any other nucleoside analogues
  • Dihydropyrimidine dehydrogenase (DPD) deficiency
  • History of uncontrolled seizures, central nervous system disorders, or psychiatric disability judged by the investigator to be clinically significant, precluding or interfering with compliance for oral drug intake
Terms in these criteria, in plain language(6)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Histologically or cytologically confirmed

The diagnosis was confirmed by looking at a sample under a microscope: tissue from a biopsy or surgery (histology), or cells from a fluid or needle sample (cytology).

Your pathology report is the document that shows this.

ECOG performance status

A scale of how much an illness limits everyday activity. For people being assessed to join a study, scores run from 0 (fully active) to 4; lower is more active.

0
Fully active, no restrictions.
1
Limited in strenuous activity, but walking and able to do light work, such as housework or office work.
2
Walking and able to look after yourself, but unable to work; up and about more than half of waking hours.
3
Able to look after yourself only in part; in bed or a chair more than half of waking hours.
4
Unable to look after yourself at all; in bed or a chair all day.

Studies most often ask for 0–1 or 0–2. Your doctor gives the score; the WHO scale uses the same steps. The full scale also has 5, which records death.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Cancer (malignancy)

Malignancy means cancer. Criteria about another or earlier malignancy ask whether you have had a different cancer, usually within a set number of years.

Some are commonly allowed, such as treated skin cancers other than melanoma and early cancers removed completely — check the exceptions this study lists.

Clinically significant

Judged by the study doctor to matter for your health or for the study. It is a doctor’s decision, so ask the study team if you are unsure whether something counts.

Informed consent

Before you join, the study team explains what taking part involves — its purpose, what happens, the risks and possible benefits — and answers your questions, so you can decide freely. Consent is usually recorded on a form (the informed consent form, ICF) signed by you or, where the law allows, by someone legally authorized to decide for you.

You can keep asking questions during the study, you are told of new information that matters, and you can choose to leave at any time.

05

Study design

Phase
Phase 2
Primary purpose
Treatment
Allocation
Not applicable
Intervention model
Single group
Masking
None (open label)
Enrollment
60 participants (actual)

Study arms

  • Experimental
    Capecitabine+Oxaliplatin

    Eligible participants received capecitabine 1000 milligrams per square meter (mg/m\^2) on Days 1-14, and 825 mg/m\^2 on Days 22-35 and 43-56 twice a day (bid) orally, along with oxaliplatin as a 2-hour intravenous (iv) infusion of 130 mg/m\^2/once a day (d) on Day 1 and 50 mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy. Participants received radiation therapy having a fraction dose of 1.8 gray (Gy)/day, 5 days a week, for five consecutive weeks starting on Day 22 of the treatment period. Participants, who completed the treatment period, underwent surgery at Week 14.

    Drug: Capecitabine · Drug: Oxaliplatin

Interventions

  • Capecitabine is available as 50 mg and 500 mg tablets. It will be administered as a 1000mg/m\^2 bid orally on Days 1-14, and at a dose of 825mg/m\^2 bid on Days 22-35 and 43-56.

    Also known as: Xeloda, Ro09-1978

  • Oxaliplatin is available in vials containing 50 mg or 100 mg. It will be administered as a oxaliplatin 130mg/m\^2/d intravenously on Day 1 and 50mg/m\^2/d on Days 22, 29, 43 and 50 prior to radiotherapy up to Week 9 followed by surgery period.

    Also known as: Eloxatin

06

What researchers measure

Primary outcomes

  1. Percentage of Participants With Pathological Complete Tumor Response

    Pathological complete tumor response was defined as grade 3 or 4 in the histological grading of regression according to Dworak classification. Grade 0 is no regression; Grade 1 is dominant tumor mass with obvious fibrosis and/or vasculopathy; Grade 2 is dominantly fibrotic changes with few tumor cells or groups; Grade 3 is defined as very few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance; Grade 4 is defined as no tumor cells, only fibrotic mass (total regression or response).

    Time frame: Up to Week 16

Secondary outcomes

  1. Percentage of Participants With Sphincter-preservation

    Percentage of participants with sphincter-preservation is reported.

    Time frame: Up to Week 16

  2. Number of Participants With Marked Laboratory Abnormalities

    Number of participants with marked laboratory abnormalities is reported.

    Time frame: Up to Week 16

  3. Percentage of Participants With Resection (R0) in Participants With T4 Rectal Cancer

    R0 resection was defined as complete resection of the tumor with adequate tumor-free margins and regional lymph node extirpation as confirmed by pathology after pre-operative chemotherapy plus capecitabine + oxaliplatin therapy.

    Time frame: Up to Week 16

  4. Percentage of Participants With Downstaging of Primary Tumor and/or Lymph Nodes

    Downstaging of primary tumor (T) and/or lymph nodes (N) was defined as decrease by 1 point in T-value and/or N-value (comparing at screening and after treatment). It was assessed by colonoscopy, pathology, endosonography of rectum, chest X-ray, abdominopelvic Computed Tomography and Magnetic Resonance Imaging. Staging for tumor are: TX (primary tumor cannot be assessed), T0 (no evidence of primary tumor), Tis (carcinoma in situ), T1 (tumor invades submucosa), T2 (tumor invades muscularis propria), T3 (tumor invades through muscularis propria into subserosa/into non-peritonealized pericolic/perirectal tissues, T4 (tumor directly invades other organs or structures). Staging for lymph nodes are: NX (regional lymph nodes cannot be assessed), N0 (no regional lymph node metastasis), N1 (metastasis in 1 to 3 regional lymph nodes), N2 (metastasis in 4 or more regional lymph nodes).

    Time frame: From screening to Week 16

  5. Percentage of Participants With Pathological Incomplete Tumor Response

    Pathological incomplete tumor response was defined as grade 1 or 2 in the histological grading of regression according to Dworak grading of regression. Pathological incomplete tumor response rate, Grade 1: dominant tumor mass with obvious fibrosis and/or vasculopathy; Grade 2: dominantly fibrotic changes with few tumor cells or groups (easy to find) were assessed.

    Time frame: Up to Week 16

  6. Number of Participants With Any Adverse Events and Serious Adverse Events

    An adverse event (AE) is defined as any untoward medical occurrence in participants or clinical investigation participants administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.

    Time frame: Up to Week 16

07

Results

Posted Nov 9, 2016

Participant flow

A total of 60 participants were enrolled in this study conducted from 30 March 2005 to 28 November 2006 at 6 centers in Switzerland.

Participant flow — Overall Study
MilestoneCapecitabine + Oxaliplatin
Started60
Completed58
Not completed2
Withdrew: Death1
Withdrew: Withdrawal by subject1

Outcome measures

PrimaryPercentage of Participants With Pathological Complete Tumor Response

Pathological complete tumor response was defined as grade 3 or 4 in the histological grading of regression according to Dworak classification. Grade 0 is no regression; Grade 1 is dominant tumor mass with obvious fibrosis and/or vasculopathy; Grade 2 is dominantly fibrotic changes with few tumor cells or groups; Grade 3 is defined as very few (difficult to find microscopically) tumor cells in fibrotic tissue with or without mucous substance; Grade 4 is defined as no tumor cells, only fibrotic mass (total regression or response).

Time frame:
Up to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Pathological Complete Tumor Response
Percentage of participantsCapecitabine + Oxaliplatin
Percentage of Participants With Pathological Complete Tumor Response23 (13.4 to 36.0)
SecondaryPercentage of Participants With Sphincter-preservation

Percentage of participants with sphincter-preservation is reported.

Time frame:
Up to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Sphincter-preservation
Percentage of participantsCapecitabine + Oxaliplatin
Percentage of Participants With Sphincter-preservation84.48
SecondaryNumber of Participants With Marked Laboratory Abnormalities

Number of participants with marked laboratory abnormalities is reported.

Time frame:
Up to Week 16
Reported as:
Number · Participants
Number of Participants With Marked Laboratory Abnormalities
ParticipantsCapecitabine + Oxaliplatin
Hemoglobin7
Hematocrit7
Erythrocytes16
Leucocytes total8
Neutrophils9
Basophils1
Eosinophils2
Monocytes2
Lymphocytes42
Platelets13
ASAT/SGOT2
ALAT/SGPT10
Serum albumin3
Total protein2
Serum creatinine2
Glucose13
Sodium2
Potassium2
Calcium2
SecondaryPercentage of Participants With Resection (R0) in Participants With T4 Rectal Cancer

R0 resection was defined as complete resection of the tumor with adequate tumor-free margins and regional lymph node extirpation as confirmed by pathology after pre-operative chemotherapy plus capecitabine + oxaliplatin therapy.

Time frame:
Up to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Resection (R0) in Participants With T4 Rectal Cancer
Percentage of participantsCapecitabine + Oxaliplatin
Percentage of Participants With Resection (R0) in Participants With T4 Rectal Cancer100
SecondaryPercentage of Participants With Downstaging of Primary Tumor and/or Lymph Nodes

Downstaging of primary tumor (T) and/or lymph nodes (N) was defined as decrease by 1 point in T-value and/or N-value (comparing at screening and after treatment). It was assessed by colonoscopy, pathology, endosonography of rectum, chest X-ray, abdominopelvic Computed Tomography and Magnetic Resonance Imaging. Staging for tumor are: TX (primary tumor cannot be assessed), T0 (no evidence of primary tumor), Tis (carcinoma in situ), T1 (tumor invades submucosa), T2 (tumor invades muscularis propria), T3 (tumor invades through muscularis propria into subserosa/into non-peritonealized pericolic/perirectal tissues, T4 (tumor directly invades other organs or structures). Staging for lymph nodes are: NX (regional lymph nodes cannot be assessed), N0 (no regional lymph node metastasis), N1 (metastasis in 1 to 3 regional lymph nodes), N2 (metastasis in 4 or more regional lymph nodes).

Time frame:
From screening to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Downstaging of Primary Tumor and/or Lymph Nodes
Percentage of participantsCapecitabine + Oxaliplatin
T stage47
N stage48
Overall65
SecondaryPercentage of Participants With Pathological Incomplete Tumor Response

Pathological incomplete tumor response was defined as grade 1 or 2 in the histological grading of regression according to Dworak grading of regression. Pathological incomplete tumor response rate, Grade 1: dominant tumor mass with obvious fibrosis and/or vasculopathy; Grade 2: dominantly fibrotic changes with few tumor cells or groups (easy to find) were assessed.

Time frame:
Up to Week 16
Reported as:
Number · Percentage of participants
Percentage of Participants With Pathological Incomplete Tumor Response
Percentage of participantsCapecitabine + Oxaliplatin
Percentage of Participants With Pathological Incomplete Tumor Response72 (58.6 to 82.5)
SecondaryNumber of Participants With Any Adverse Events and Serious Adverse Events

An adverse event (AE) is defined as any untoward medical occurrence in participants or clinical investigation participants administered a pharmaceutical product and which did not necessarily have to have a causal relationship with this treatment. A serious adverse event (SAE) is any untoward medical occurrence that at any dose results in death, are life threatening, requires hospitalization or prolongation of hospitalization or results in disability/incapacity, and congenital anomaly/birth defect.

Time frame:
Up to Week 16
Reported as:
Number · Participants
Number of Participants With Any Adverse Events and Serious Adverse Events
ParticipantsCapecitabine + Oxaliplatin
Any AEs59
Any SAEs8

Adverse events

Collected over Up to Week 16. Non-serious events are listed at a 5% frequency threshold.

Adverse event summary by group
GroupDeathsSeriousOther
Capecitabine + Oxaliplatin—8/60 (13.3%)57/60 (95%)
Most frequent serious events
Most frequent serious events
EventCapecitabine + Oxaliplatin
DiarrhoeaGastrointestinal disorders5/60
Abdominal PainGastrointestinal disorders1/60
Anal HaemorrhageGastrointestinal disorders1/60
ColitisGastrointestinal disorders1/60
ProctitisGastrointestinal disorders1/60
StomatitisGastrointestinal disorders1/60
SubileusGastrointestinal disorders1/60
SepsisInfections and infestations1/60
Most frequent other events
Showing 10 of 23
Most frequent other events
EventCapecitabine + Oxaliplatin
DiarrhoeaGastrointestinal disorders42/60
FatigueGeneral disorders27/60
NauseaGastrointestinal disorders20/60
ProctitisGastrointestinal disorders14/60
NeuropathyNervous system disorders13/60
PollakiuriaRenal and urinary disorders12/60
AnorexiaMetabolism and nutrition disorders11/60
ParaesthesiaNervous system disorders10/60
Abdominal PainGastrointestinal disorders8/60
VomitingGastrointestinal disorders8/60

Baseline characteristics

Safety population included all the participants who received at least one dose of any of the study treatments and who had a baseline assessment.

Age, Continuous
Age, Continuous(years)Capecitabine + Oxaliplatin
Median61 (35 to 77)
Gender
Gender(Participants)Capecitabine + Oxaliplatin
Female14
Male46
08

Study locations

6 sites
  • Basel, 4031, Switzerland
  • Chur, 7000, Switzerland
  • Luzern, 6004, Switzerland
  • St. Gallen, 9007, Switzerland
  • Zürich, 8037, Switzerland
  • Zürich, 8063, Switzerland
09

Timeline

Tracking since Sep 25, 2026
Not marked actual or estimatedDates not marked actual or estimated

The record gives a start of Mar 2005, a primary completion of Aug 2006 and a completion of Nov 2006. It does not say whether these dates are actual or estimated.

Results were first posted in Nov 2016, 10 years 3 months after primary completion.

How these figures are worked out, and which studies are left out of them.

Registered
Feb 25, 2016
First posted
Feb 29, 2016
Start
Mar 2005
Primary completionActual
Aug 2006
CompletionActual
Nov 2006
Results first posted
Nov 9, 2016
Last update
Jan 11, 2017
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
No changes since tracking began. The registry record was last updated on Jan 11, 2017, before this site started recording changes on Sep 25, 2026. Its history is on ClinicalTrials.gov ↗
10

Registry details

Key details

Study ID
NCT02694718
Lead sponsor
Hoffmann-La Roche
Collaborators
Sanofi-Synthélabo (Schweiz) AG
Responsible party
Sponsor
First posted
Feb 29, 2016
Start date
Mar 2005
Primary completion
Aug 2006
Completion
Nov 2006
Results posted
Nov 9, 2016
Last update
Jan 11, 2017

Study contacts

Clinical Trials
study chair · Hoffmann-La Roche
View the source record on ClinicalTrials.gov ↗

Not currently enrolling

This study is completed, as verified in Feb 2016. You cannot join it, but the record below documents what was studied.

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Studies of the drugs tested here: Capecitabine · Oxaliplatin

Start the discussion